Your browser doesn't support javascript.
loading
Bevacizumab-induced laryngeal necrosis.
Hartl, D M; Bahleda, R; Hollebecque, A; Bosq, J; Massard, C; Soria, J C.
Afiliação
  • Hartl DM; Department of Head and Neck Oncology, Institut Gustave Roussy, Villejuif. Electronic address: dana.hartl@igr.fr.
  • Bahleda R; Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif.
  • Hollebecque A; Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif.
  • Bosq J; Department of Pathology, Institut Gustave Roussy, Villejuif, France.
  • Massard C; Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif.
  • Soria JC; Department of Medical Oncology-SITEP (Service des Innovations Thérapeutiques Précoces), Institut Gustave Roussy, Villejuif.
Ann Oncol ; 23(1): 276-278, 2012 Jan.
Article em En | MEDLINE | ID: mdl-22056850
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Laringe / Anticorpos Monoclonais Humanizados / Antineoplásicos Idioma: En Ano de publicação: 2012 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças da Laringe / Anticorpos Monoclonais Humanizados / Antineoplásicos Idioma: En Ano de publicação: 2012 Tipo de documento: Article